Ojjaara (momelotinib)

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

JAK2 inhibitor, JAK1 inhibitor, ACVR1 inhibitor

Related drugs:

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	momelotinib Sensitive: C2 – Inclusion Criteria momelotinib Sensitive : C2	momelotinib Sensitive: C2 – Inclusion Criteria momelotinib Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	selumetinib + momelotinib Sensitive: D – Preclinical selumetinib + momelotinib Sensitive : D	selumetinib + momelotinib Sensitive: D – Preclinical selumetinib + momelotinib Sensitive : D

Associations
(2)